![Christine Brennan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christine Brennan
Directeur/Membre du Conseil chez
Redona Therapeutics, Inc.
Profil
Dr. Christine Brennan is a Vice President at Johnson & Johnson Innovation - JJDC, Inc. and an Investment Committee Member at Pathway To Cures.
She is on the Board of Directors at Redona Therapeutics, Inc.
Dr. Brennan was previously employed as an Independent Director by Boundless Bio, Inc., a Managing Director by Vertex Ventures HC, a Partner by Merck Research Ventures, a Principal by Novartis Venture Funds (USA), a Chief Business Officer by Vitae Pharmaceuticals inc, a Director-Business Development by EnVivo Pharmaceuticals, Inc., a Product Manager-Cardizem LA by Biovail Corp.
International, a Scientific Analyst by Cogent Neuroscience, Inc., a Senior Consultant by Kendall Strategies, Inc., and an Executive Director, Head-Strategy & Operations by Novartis Institutes for Biomedical Research, Inc. She also served on the board at Therini Bio, Inc., Altimmune, Inc. /Old/, Impresa Management LLC, Alector, Inc., Entrada Therapeutics, Inc. and Tallac Therapeutics, Inc.
She received her undergraduate degree from the University of New Hampshire and a doctorate degree from Dartmouth Medical School.
Postes actifs de Christine Brennan
| Sociétés | Poste | Début |
|---|---|---|
Pathway To Cures
 Pathway To Cures Investment ManagersFinance Pathway To Cures invests in companies located in the United States. The firm focuses on medical technologies sectors. It provides financing for early stage capital requirements. | Membre du Comité d'Investissement | 27/02/2023 |
Redona Therapeutics, Inc.
 Redona Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutics for cancer and autoimmune diseases | Directeur/Membre du Conseil | - |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC invests in private and public companies located across the globe. The firm focuses on innovative medicine, health equity and medtech sectors. It provides financing for seed, early, and later stage capital requirements. | Private Equity Investor | 01/03/2026 |
Anciens postes connus de Christine Brennan
| Sociétés | Poste | Fin |
|---|---|---|
| BOUNDLESS BIO, INC. | Directeur/Membre du Conseil | 03/03/2026 |
Merck Research Ventures
 Merck Research Ventures Investment ManagersFinance Merck Research invests in companies located globally. The firm targets companies operating in the therapeutics sector. It participates in seed and early stage capital requirements with an investment size of up to USD 25 million. The firm acts as a lead and co-lead investor and takes a seat on the board of directors. It also makes follow-on investments and does not invest in medical devices, diagnostic platforms and digital health. | Private Equity Investor | 01/02/2022 |
Therini Bio, Inc.
 Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in halt chronic neuroinflammation and neuronal damage caused by vascular injury to treat severe neurological & retinal diseases | Directeur/Membre du Conseil | 01/01/2021 |
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Private Equity Investor | 01/05/2017 |
| VITAE PHARMACEUTICALS INC | Corporate Officer/Principal | 01/11/2013 |
Formation de Christine Brennan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
21
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 21 |
|---|---|
Biovail Corp.
 Biovail Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
FORUM Pharmaceuticals, Inc.
 FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for central nervous system disorders | Health Technology |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC invests in private and public companies located across the globe. The firm focuses on innovative medicine, health equity and medtech sectors. It provides financing for seed, early, and later stage capital requirements. | Finance |
University of New Hampshire
 University of New Hampshire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vitae Pharmaceuticals LLC
 Vitae Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops small molecule compounds | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Altimmune, Inc. /Old/
 Altimmune, Inc. /Old/ Medical/Nursing ServicesHealth Services Develops vaccines and other biological products | Health Services |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Finance |
Dartmouth Medical School
 Dartmouth Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cogent Neuroscience, Inc. | |
Alector, Inc.
 Alector, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for Alzheimer’s disease and other neurodegenerative disorders | Health Technology |
Impresa Management LLC
 Impresa Management LLC Investment ManagersFinance F-Prime invests in companies located in Asia, Europe, North America and South America. The firm targets companies operating in the fields of life sciences, technology, healthtech & services and crypto sectors. It provides financing for seed, early and later stage transactions. | Finance |
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research invests in companies located globally. The firm targets companies operating in the therapeutics sector. It participates in seed and early stage capital requirements with an investment size of up to USD 25 million. The firm acts as a lead and co-lead investor and takes a seat on the board of directors. It also makes follow-on investments and does not invest in medical devices, diagnostic platforms and digital health. | Finance |
Vertex Ventures HC
 Vertex Ventures HC Investment ManagersFinance Vertex Ventures invests in companies located across the globe. The firm targets companies operating in the fields of healthcare, medical and technology sectors. It provides financing for early stage capital requirements. | Finance |
Redona Therapeutics, Inc.
Redona Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutics for cancer and autoimmune diseases | Health Technology |
Entrada Therapeutics, Inc.
 Entrada Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for rare neuromuscular diseases | Health Technology |
Therini Bio, Inc.
Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in halt chronic neuroinflammation and neuronal damage caused by vascular injury to treat severe neurological & retinal diseases | Commercial Services |
Boundless Bio, Inc.
 Boundless Bio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage oncology company that develops cancer therapeutics | Health Technology |
Tallac Therapeutics, Inc.
 Tallac Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Engages in research and development of immunomodulation polynucleotides | Health Technology |
Pathway To Cures
Pathway To Cures Investment ManagersFinance Pathway To Cures invests in companies located in the United States. The firm focuses on medical technologies sectors. It provides financing for early stage capital requirements. | Finance |
Kendall Strategies, Inc. |
